Townes Shatara V, Furst Daniel E, Thenkondar Anuradha
Department of Rheumatology, University of California-Los Angeles, Los Angeles, CA, USA.
Sri Ramachandra Medical College and Research Institute, Chennai, India.
Open Access Rheumatol. 2012 Aug 9;4:87-92. doi: 10.2147/OARRR.S14563. eCollection 2012.
To determine the impact of tocilizumab on physical function and quality of life in patients diagnosed with rheumatoid arthritis.
A systematic literature review was performed to select for trials that could be used to examine the impact of tocilizumab on patients in terms of health-related physical function, quality of life, and quality of sleep. By examining background therapy, disease duration, and remission rates, we were able to determine the impact that a dose of tocilizumab has on various patients.
A total of 2617 tocilizumab-treated patients and 1271 controls were available for this study. Tocilizumab improved the Health Assessment Questionnaire Disability Index score statistically in comparison to the controls, with odds ratios from 1.4 to 7.0. Tocilizumab improved the physical function measure substantially more than the minimal clinically important difference (MCID) (5 units) - 8.9 and 9.7 - compared to 4.1 and 5.0 for controls. Seven and nine units of improvement were observed when measuring fatigue in rheumatoid arthritis patients. Using the Epworth Sleepiness Scale, we found that sleep improved (from 7.7 [3.1] to 3.4 [2.2]).
Tocilizumab improves function and quality of life and decreases fatigue in patients with rheumatoid arthritis.
确定托珠单抗对类风湿关节炎患者身体功能和生活质量的影响。
进行了一项系统的文献综述，以筛选可用于研究托珠单抗在健康相关身体功能、生活质量和睡眠质量方面对患者影响的试验。通过研究背景治疗、疾病持续时间和缓解率，我们能够确定一剂托珠单抗对不同患者的影响。
本研究共纳入2617例接受托珠单抗治疗的患者和1271例对照。与对照组相比，托珠单抗在统计学上改善了健康评估问卷残疾指数评分，比值比为1.4至7.0。托珠单抗对身体功能的改善程度明显超过最小临床重要差异（MCID）（5分）——分别为8.9和9.7分，而对照组为4.1分和5.0分。在测量类风湿关节炎患者的疲劳程度时，观察到改善了7分和9分。使用爱泼华嗜睡量表（Epworth Sleepiness Scale），我们发现睡眠得到了改善（从7.7[3.1]降至3.4[2.2]）。
托珠单抗可改善类风湿关节炎患者的功能和生活质量，并减轻疲劳。
